Showing posts with label Invenia Automated Breast Ultrasound System(ABUS). Show all posts
Showing posts with label Invenia Automated Breast Ultrasound System(ABUS). Show all posts

Sunday, December 30, 2018

Here are the top 5 most read ultrasound posts of 2018



With only a few hours left for the calendar year 2018 to come to an end, take a look at the top 5 most read ultrasound posts of the year as we gear up to look forward to another year of medical advances and health research. 


Blob and Bagel sign on Ultrasound can be labeled as definitive for Ectopic Pregnancy
Women with the Blob and Bagel ultrasound sign should be reclassified from having ‘probable’ ectopic pregnancy (EP) to ‘definitive’ EP and should be treated as such reports the result of a large retrospective cohort study published March 11, 2018, in Journal of Ultrasound in Obstetrics and Gynecology.
Ectopic Pregnancy is still the leading cause of first-trimester maternal deaths and constitutes 4% of all pregnancy-related deaths. The incidence of ectopic is highest in women undergoing In-Vitro Fertilization (IVF) and ranges from 4% to 11% of all pregnancies.

Novel cross-over sign in cesarean scar pregnancy helps predicts the risk of invasive placentation
First trimester ultrasound scan evaluating the relationship between the gestational sac and the endometrial line in women with cesarean scar pregnancy(CSP) helps predicts the development of abnormally invasive placenta (AIP) and consecutive intra and post-operative surgical morbidities reports the results of a retrospective case series published in the Journal of International Society of Ultrasound in Obstetrics and Gynecology.

Recent advances in prenatal imaging and increase rate of cesarean sections have led to increased diagnosis of CSP. Although, most of the patients with CSP present with severe hemorrhage or rupture uterus, that requires emergency surgical management, few advances further, evolving into AIP. 

Negative sliding sign by ultrasound in repeat cesarean section predicts the presence of severe intrabdominal adhesions
A negative sliding sign by ultrasonography (USG) in patients with previous cesarean section helps alert the surgeon to expect massive intraabdominal adhesions, difficult repeat cesarean section and need of blood transfusion during surgery reports the results of a prospective observational study published ahead of print in the February issue of Journal Obstetrics and Gynecology.

Postoperative adhesion formation is quite prevalent after an abdominal or pelvic surgery and any method which can predict the existence of such adhesion could optimize the outcome of current surgery.

GE Healthcare introduces its new automated breast ultrasound for dense breast
There could not have been a more appropriate time for the launch of GE Healthcare new Invenia Automated Breast Ultrasound (ABUS) 2.0 than October, which is celebrated as breast cancer awareness month. The Invenia ABUS is the only FDA approved 3D ultrasound system for supplemental screening for breast cancer along with mammography.

In conjunction with mammography, it increases the chances of cancer detection in the dense breast by 55%. All breasts are not the same, the density of breast is determined by a proportion of fat and breast tissue—when the percentage of breast tissue exceeds that of fat, breasts are labeled as being dense.

A practical guide to count ovarian antral follicles by ultrasound
A consensus opinion highlighting the main techniques of ovarian antral follicle count (AFC), and providing recommendations for future research is published in the special issue on Reproductive Medicine of the journal Ultrasound in Obstetrics and Gynecology.

The consensus makes several recommendations for varied methods used in counting the antral follicles, but no single method is superior over others and the choice should make the best use of resources available in a setting.


Here are the top 10 most read posts of 2018



With only a few hours left for the calendar year 2018 to come to an end, take a look at the top 10 most read posts of the year as we gear up to look forward to another year of medical advances and health research. 

ACOG guidance on prevention of surgical-site infection in gynecologic surgery
Surgical site infections (SSIs) after gynecological surgery is a significant cause of postoperative morbidity leading to repeated hospital visits.  These infections also incur heavy social and economic burden on patients and the healthcare system.
The recent ACOG practice bulletin is published in the June issue of Journal of Obstetrics and Gynecology and replaces Practice Bulletin Number 104, May 2009, and Committee Opinion Number 571, September 2013.

New approach to ovarian cystectomy: Transvaginal natural orifice transluminal endoscopic surgery
Natural orifice transluminal endoscopic surgery (NOTES) is a challenging minimally invasive procedure where ‘scarless’ abdominal surgeries are performed through an endoscope inserted through a natural orifice (mouth, anus, vagina, and urethra) and is considered as a less invasive approach to laparoscopic surgeries. 

NOTES is considered a logical next step in the evolution of minimally invasive surgery, and the first NOTES procedure in humans is often considered to be a transgastric appendectomy performed in India in 2006 which was presented but not reported in manuscript form.

Blob and Bagel sign on Ultrasound can be labeled as definitive for Ectopic Pregnancy
Women with the Blob and Bagel ultrasound sign should be reclassified from having ‘probable’ ectopic pregnancy (EP) to ‘definitive’ EP and should be treated as such reports the result of a large retrospective cohort study published March 11, 2018, in Journal of Ultrasound in Obstetrics and Gynecology.
Ectopic Pregnancy is still the leading cause of first-trimester maternal deaths and constitutes 4% of all pregnancy-related deaths. The incidence of ectopic is highest in women undergoing In-Vitro Fertilization (IVF) and ranges from 4% to 11% of all pregnancies.


Novel cross-over sign in cesarean scar pregnancy helps predicts the risk of invasive placentation
First trimester ultrasound scan evaluating the relationship between the gestational sac and the endometrial line in women with cesarean scar pregnancy(CSP) helps predicts the development of abnormally invasive placenta (AIP) and consecutive intra and post-operative surgical morbidities reports the results of a retrospective case series published in the Journal of International Society of Ultrasound in Obstetrics and Gynecology.

Recent advances in prenatal imaging and increase rate of cesarean sections have led to increased diagnosis of CSP. Although, most of the patients with CSP present with severe hemorrhage or rupture uterus, that requires emergency surgical management, few advances further, evolving into AIP. 


Negative sliding sign by ultrasound in repeat cesarean section predicts the presence of severe intrabdominal adhesions
A negative sliding sign by ultrasonography (USG) in patients with previous cesarean section helps alert the surgeon to expect massive intraabdominal adhesions, difficult repeat cesarean section and need of blood transfusion during surgery reports the results of a prospective observational study published ahead of print in the February issue of Journal Obstetrics and Gynecology.
Postoperative adhesion formation is quite prevalent after an abdominal or pelvic surgery and any method which can predict the existence of such adhesion could optimize the outcome of current surgery.

GE Healthcare introduces its new automated breast ultrasound for dense breast
There could not have been a more appropriate time for the launch of GE Healthcare new Invenia Automated Breast Ultrasound (ABUS) 2.0 than October, which is celebrated as breast cancer awareness month. The Invenia ABUS is the only FDA approved 3D ultrasound system for supplemental screening for breast cancer along with mammography.
In conjunction with mammography, it increases the chances of cancer detection in the dense breast by 55%. All breasts are not the same, the density of breast is determined by a proportion of fat and breast tissue—when the percentage of breast tissue exceeds that of fat, breasts are labeled as being dense.

A practical guide to count ovarian antral follicles by ultrasound
A consensus opinion highlighting the main techniques of ovarian antral follicle count (AFC), and providing recommendations for future research is published in the special issue on Reproductive Medicine of the journal Ultrasound in Obstetrics and Gynecology.
The consensus makes several recommendations for varied methods used in counting the antral follicles, but no single method is superior over others and the choice should make the best use of resources available in a setting.

ACOG update: Letrozole is the first line therapy for ovulation induction in PCOS
The American College of Obstetricians and Gynecologists (ACOG) now recommends Letrozole (aromatase inhibitor) as the first-line treatment for ovulation induction in women with Polycystic Ovarian Syndrome (PCOS) due to data demonstrating increased ovulation rates, clinical pregnancy rates and live-birth rate vs clomiphene citrate. The guidelines are published as Practice Bulletin No. 194 in the June issue of Journal Obstetrics and Gynecology.
This replaces the Practice Bulletin Number 108, published October 2009, which recommends letrozole as first-line therapy for ovulation induction only in women with PCOS and a BMI greater than 30.

Sonographically measured fetal head circumference ≥35 cm at term increases the odds of cesarean delivery
Sonographically measured fetal head circumference ≥35 cm, within a week of delivery increases the odds of unplanned cesarean section by 75% report the results of multicenter observational study accepted for publication in American Journal of Obstetrics and Gynecology.

Currently, In the US, one in every third baby is born by cesarean section and the high rate is a cause of concern for the healthcare industry.

FDA approves a bedside test for assessing the risk of spontaneous preterm birth
QIAGEN won FDA approval for marketing its Novel PartoSure® point of care test for estimating the risk of spontaneous preterm birth in patients who present with symptoms of preterm labor. PartoSure represents a breakthrough in research and development of diagnostic tests for preterm birth.

Predicting preterm birth is a diagnostic challenge and nearly 85% of patients admitted to the hospital for threatened preterm labor (PTL) do not deliver within the next 7 days, resulting in unnecessary interventions.

Sunday, October 8, 2017

The Future of Breast Cancer Detection is Already Here | Kevin Kelly | TEDx Talk


October is Breast Cancer Awareness month. Dr. Kelly is one of this country’s leading authorities on using ultrasound to detect cancers in women with dense breast tissue and/or implants. Nearly 20 plus years of research have provided sufficient evidence to link dense breast tissue and increased risk of missing cancer diagnosis by screening mammography. As the breast density increases, the reliability of mammogram as a screening tool for picking up breast malignancy decreases.

In his TEDx Talk, Dr Kelly is calling all women with dense breasts or implants to know that  small, curable cancers are often missed by mammography. Following Dr. Papanicolaou’s 30-year struggle to gain acceptance of the Pap smear for detection of cervical cancer, Dr. Kelly is working to do the same for an automated ultrasound technology that finds cancers when they are very small and very curable.

Dr. Kevin Kelly is passionate and dedicated to the early detection of breast cancer. His goal is to educate women about the importance of understanding their breast type so they can make informed decisions about their screening options. Kevin is the Medical Director of The Breast Ultrasound Center in Pasadena, CA, and has been in private practice as a diagnostic radiologist for 34 years.

Related Links on early detection of cancer in dense breast:

Here is the TEDx talk: 







Thursday, April 27, 2017

‘One size fits all’ breast imaging is a thing of past with new personalized breast exams by Automated Breast Ultrasound (ABUS).

Mammography misses 30% of breast cancers in dense breast which means that nearly 40% of women have the chance of missing breast cancer by simple screening mammography. Now it is possible to individualize breast imaging for each patient using multimodality approach.

Starting with personal and family history, followed by gold standard screening mammography with new technology of breast tomosynthesis, we can know the personal biology of the patient.

 Knowing that the woman has dense breast after the initial screening Automated Breast Ultrasound (ABUS) can be performed which increases the chances of cancer detections even after negative mammography.  

Using all this tool synergistically it is possible to increase the breast cancer detection rate by 55 percent over mammography alone.


More information about the ABUS by GE healthcare can be found here: https://obgynupdated.blogspot.com/2017/03/innovative-breast-ultrasound-system-for.html


More information about screening modalities other than mammography can be found here: https://obgynupdated.blogspot.com/2017/04/looking-beyond-screening-mammography-in.html

Know more about personalized breast cancer screening by watching this video.

Wednesday, March 22, 2017

Innovative Breast Ultrasound system for cancer screening in women with dense breast.


Courtesy: GE systems
Mammography is the gold standard for early detection and cancer screening for breast cancer, however it may miss the cancer in about one third of patients with dense breast tissue. According to a study about 40% of women in US have dense breast.

Dense breast also increases the likelihood of developing cancer by 5 to 6 times as compared to women with normal breast density.  Often the cancers are detected very late in women with dense tissue because of imaging difficulty.

GE Introduced a new version of its automated breast ultrasound system ‘the Invenia Automated Breast Ultrasound System(ABUS)’.


Courtesy: GE systems

GE says, “Invenia ABUS is a comfortable, non-ionizing alternative to other supplemental screening options for women with dense breast tissue. When used in addition to mammography, Invenia ABUS can improve breast cancer detection by 35.7 percent over mammography alone.” It is not a substitute for mammography but a non-ionizing adjunct to the procedure and can detect early stage, node negative, invasive cancers.

The Invenia ABUS system is designed for screening and it shifts the diagnostic approach from hardware based system to software based system. The system creates a reproducible, fully automated scan that takes 15 minutes to complete. It captures whole breast three dimensional images that are displayed at the workstation as 2mm coronal view slices.


It also adjusts the signals levels in the nipple area so that it looks like surrounding tissue enhancing visualization. Other distinct features helping in better image quality and increasing visualization are Breast Border Detection and Chest Wall Detection.

The reverse curve transducer is designed to enhance the breast coverage and patient’s comfort during examination. Patients also report to be more comfortable because of absence of the pressing and pain sensation so common to mammography.

The system received FDA approval in 2014 and currently 180 hospitals are using it. 

The European Asymptomatic Screening Study screened 1,668 women between the ages of 40-74 with ABUS in a 15-minute exam after they had already undergone digital mammography screening. The results showed a 57 percent relative increase in cancer detection.

The findings were equivalent to 6.6 cancers detected per 1,000 women, compared with 4.2 percent of those who received mammography alone.

In a recent interview with medgadget[1] at the National Consortium of Breast Centers Conference,[2]Dr. Georgia Giakoumis Spear of NorthShore University Health System affirmed that ABUS is complementary to mammography and it is not meant for replacing it.  The NorthShore hospital is using the system for 15 months and is extremely satisfied with the results. They found about 25 cases of occult breast cancer not detected by mammography. 





[1] http://www.medgadget.com/2017/03/breast-cancer-detection-using-ultrasound-interview-dr-georgia-giakoumis-spear-northshore-university-health-system.html
[2] https://www2.breastcare.org/welcome-to-the-annual-national-interdisciplinary-breast-center-conference/